Lopinavir CAS 192725-17-0 API Anti-HIV HIV Protease Inhibitor COVID-19 High Munditia

Description:

Nomen chemicum: Lopinavir

CAS: 192725-17-0

Aspectus: Alba ad Off album pulveris

Tentamen (HPLC): 98.0%~ 102.0%

Selective Peptidomimetic HIV-1 Protease Inhibitor

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple cum High puritate et stabulo Quality
Nomen chemicum: Lopinavir
CAS: 192725-17-0
Potentissima, selectiva Peptidomimetica HIV-1 Protease Inhibitor
COVID-19 Related Research Product
API High Quality, Commercial Production

Chemical Properties:

Nomen chemicum	Lopinavir
Synonyma	LPV;ABT-378;Kaletra
CAS Number	192725-17-0
CATTUS Number	RF-API73
Stock Status	In Stock, Productio Ascendite usque ad Centum chiliogrammata
Formulae hypotheticae	C37H48N4O5
M. Pondus	628.81
Long-Term PRAECLUSIO	Copia Diu terminus in 2-8℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White pulveris
Solubilitas	Sponte solutum in Methanol et Ethanol, solutum in 2-Propanol
Lepidium sativum IR	Effusio spectri experimenti ultrarubrum concordat cum spectro relationis vexillum
Lepidium sativum HPLC	Retentio tempus specimen probati correspondet relationis vexillum
Aqua Content (per KF)	≤4.0%
Imprimis Rotatione Optica	-22.0° to -26.0°
Residere in Ignition	≤0.20%
Metalla gravis	≤20ppm
Liquescens punctum	124.0 ad 127.0℃
Cinere sulphated	≤0.20%
RELICTUM Solvent (Ethanol)	≤0.50%
Substantiae cognatae	(HPLC, Area%)
immunditia 1
Impuritas B (RRT=0.07)	≤0.20%
Impuritas I (RRT=1.10)	≤0.20%
Alia immunditia	≤0.10%
immunditia 2	Alia individua immunditia ≤0.10%
Totalis immunditias de modo procedendi I et II "	≤0.70%
Totalis immunditias	≤1.0%
Temptare (per HPLC)	98.0%~ 102.0%
Test Standard	Enterprise Standard
Consuetudinem	Selective Peptidomimetic HIV-1 Protease Inhibitor, COVID-19 Related Research Product

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

FAQ:

Applicatio:

Lopinavir (ABT-378) valde potens est, inhibitor peptidomimetici selectivi protease HIV-1, cum Kis ex 1.3 ad 3.6 pM pro typo silvestri et protease mutant HIV.Lopinavir actus maturationem HIV-1 comprehendendo ita infectionem suam interclusit.Lopinavir etiam est SARS-CoV 3CLpro inhibitor cum IC50 of 14.2 μM.Lopinavir antiretroviralis classis inhibitoris protease est.Inhibitio HIV-1 protease impedit praecursorem polyprotein viralem et proventus in emissione virionum immaturae, noninfectiosarum.Pars compositionis illic tractandi HIV/AIDS.Lopinavir, sextus HIV protease inhibitor in "navir" classis, in coformulatione cum ritonavir, alius HIV protease inhibitor iam venalis (Abbott, 1996) inmissus est;Haec formula originalis Kaletra introducta est ad usum in compositione cum inhibitoribus vel nucleoside vel non-nucleoside transpositis transcripta pro auxiliis in adultis et pueris curandis.Lopinavir compositio peptidomimetica est cum nucleo structurali identico cum ritonaviro, in quo coetus terminales, praesertim valine modificati, per modum coniunctionis peptidis introductae sunt.Lopinavir potens est inhibitor competitive HIV-I protease exhibens altam potentialem contra ritonavir-resistentes mutationes.In pluribus speciebus animalis, studia pharmacokinetica cum consociatione lopinavirlritonavir ostendit modestas proprietates lopinavirorum signanter emendari coram ritonaviro, secundum Cmax et durationem actionis.